Clinical Trial Detail

NCT ID NCT02282345
Title Neoadjuvant Talazoparib for Patients With a BRCA Deleterious Mutation
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors M.D. Anderson Cancer Center
Indications

Her2-receptor negative breast cancer

Therapies

Talazoparib

Age Groups: senior adult

Additional content available in CKB BOOST